Generic Ozempic: is it available?

If you’re looking for generic Ozempic (semaglutide), we have some disappointing news. There is currently no FDA-approved generic version of Ozempic available in the United States, with patent protections lasting into the early 2030s. Read on as we explain why the wait is so long, and how you can save on the cost of Ozempic in the meantime. 

No, there currently is no FDA-approved generic form of Ozempic available in the US. The phrase "FDA-approved" is key, as you may encounter ads for generic Ozempic on less reputable websites and unlicensed "pharmacies." Semaglutide is the active ingredient in Ozempic and will likely be what it's called once a generic version is available.

For now, though, there are only four versions of semaglutide approved by the US Food and Drug Administration. These include:

• Injectable Ozempic: This once-weekly injection is FDA-approved to treat type 2 diabetes; reduce the risk of heart attack, stroke, and death in people with both type 2 diabetes and heart disease; and reduce the risk of kidney decline in people with both type 2 diabetes and kidney disease. Off-label, Ozempic may be prescribed for weight loss.

• Oral Ozempic: This daily pill is FDA-approved to treat the same conditions as injectable Ozempic. It was formerly called Rybelsus, but, as of May 2026, Rybelsus is being phased out and transitioning fully to the Ozempic pill. Inventory of original Rybelsus doses (3 mg, 7 mg, 14 mg) will remain available until depleted. 

• Injectable Wegovy: This once-weekly injection has a higher dosage of semaglutide than Ozempic. It's FDA-approved for chronic weight management in people with obesity or overweight and a weight-related health condition; fatty liver disease; and cardiovascular risk reduction in adults with obesity or overweight and heart disease.

• Oral Wegovy (aka Wegovy pill): This daily pill is FDA-approved for chronic weight management in adults with obesity or overweight and a weight-related health condition, such as high cholesterol, and to reduce the risk of heart attack, stroke, or death in adults with heart disease and obesity or overweight.

All of these medications are intended to be used alongside healthy eating habits and exercise.

Check your coverage for FDA-approved GLP-1s—for free

Check for free

There is a generic Ozempic available in Canada because the drug’s manufacturer, Novo Nordisk, did not pay an annual maintenance fee and thus allowed their exclusive patent in the country to lapse. This enabled generic drug makers to create a generic version of the drug and submit it to Health Canada for approval. 

As of May 2026, Health Canada has already approved two generic versions of injectable Ozempic. 

The earliest we can expect a generic form of Ozempic to be available is December 5, 2031. Why so far away? That date represents the day when Novo Nordisk’s (the maker of Ozempic) patent on semaglutide expires. 

When drug makers create a new medication, they usually obtain a patent that prevents others from selling a generic version for a set period of time. Currently, that time is set at 20 years from the date of patent application. 

They may also obtain marketing exclusivity for a set period of time, usually three to seven years, which further restricts competition from generic drugs. As long as patent protection, an exclusivity period, or both, are in place, generic medications cannot be approved.

Currently, Novo Nordisk’s patent on semaglutide is set to expire on December 5, 2031, so that is the earliest a generic version of semaglutide could be made available. However, that date is not a guarantee, as Novo Nordisk could opt to seek extensions on its patent protection, as it is currently doing in Brazil. 

At the same time, other pharmaceutical firms could challenge Novo Nordisk’s patent, which could lead to generic versions being made available sooner, as is currently happening in China. 

However, the US Patent Office recently rejected two claims by a pharmaceutical company seeking to challenge Novo Nordisk's patent on semaglutide.

If you are having trouble getting Ozempic, call your pharmacy to refill your prescription earlier than you normally would. You can also try shopping around at other pharmacies, including ones outside your town, or telehealth weight loss platforms such as Ro. 

If you still can’t get Ozempic — whether due to cost or changes in insurance coverage — make an appointment with your healthcare provider to discuss alternative medications.

Yes. Fortunately, there are a number of GLP-1 medications you can take instead of Ozempic. Which one will be right for you depends on what you take Ozempic for and your personal medical situation, so talk to your healthcare provider about your options. 

In the meantime, here is an overview of Ozempic alternatives so you can head to your appointment armed with knowledge.

*As of May 2026, Rybelsus has transitioned fully to the Ozempic pill; original Rybelsus inventory (3 mg, 7 mg, 14 mg) will remain available until depleted, which is why it isn't listed as a separate alternative below.

Wegovy injection and pill (semaglutide)

Wegovy (semaglutide) contains the same active ingredient as Ozempic, but in higher dosages. It’s available as a once-weekly injection or a daily pill. 

A key difference between Ozempic and Wegovy is that Wegovy is exclusively FDA-approved for weight loss in people with obesity or overweight and a weight-related condition, like high blood pressure, high cholesterol, or type 2 diabetes. Unlike Ozempic, Wegovy is not FDA-approved to treat type 2 diabetes.

Wegovy is also indicated to reduce the risk of major cardiovascular events (e.g. heart attack, stroke) in adults with obesity or overweight and cardiovascular disease. The Wegovy injection (but not the pill) is additionally approved to treat fatty liver disease in adults.

Common side effects of Wegovy include:

• Nausea

• Diarrhea

• Vomiting

• Constipation

• Abdominal pain

• Pins and needles sensations

• Headache

• Fatigue

• Upset stomach

• Dizziness

• Bloating

• Belching 

• Hypoglycemia (low blood sugar) in people with type 2 diabetes

• Flatulence

• Stomach flu

• Gastroesophageal reflux disease (GERD)

• Hair loss

Wegovy produces more weight loss than Ozempic, according to clinical studies. In a year and a half, people taking 2.4 mg of the Wegovy injection lose about 15% of their body weight, on average. 

Ozempic pill (semaglutide)

Formerly available under the brand name Rybelsus, the Ozempic pill is an oral version of the injection that’s FDA-approved to treat the same conditions: type 2 diabetes, type 2 diabetes with heart disease, and type 2 diabetes with chronic kidney disease.

Common side effects of the Ozempic pill may include:

• Nausea

• Abdominal pain

• Diarrhea

• Decreased appetite

• Vomiting

• Constipation 

Like the Ozempic injection, the Ozempic pill can also be prescribed off-label for weight loss. However, research suggests it produces less weight loss than the injection.

Mounjaro (tirzepatide)

Mounjaro (tirzepatide) is unique among (most of) the other medications on this list because it targets not just the GLP-1 receptor like Ozempic, but also the GIP (glucose-dependent insulinotropic polypeptide) receptor. 

Research suggests that being a dual receptor agonist may make Mounjaro more effective at both blood sugar control and weight loss. 

The same goes for its sister medication, Zepbound, which contains the same active ingredients in the same dosage strengths, but is FDA-approved for weight loss and obstructive sleep apnea (OSA).

Mounjaro is a once-weekly injection and comes in six dosage strengths. When compared with Ozempic, the two highest doses of Mounjaro produced more weight loss and improved blood sugar levels to a larger extent than the highest dosage (2 mg) of Ozempic in an indirect study of people with type 2 diabetes. The lowest 5 mg dose of Mounjaro produced similar improvements to Ozempic.

Mounjaro shares similar side effects with Ozempic (see below), but people may be more likely to experience side effects with Mounjaro than with Ozempic, especially with higher doses and when starting treatment. 

Common side effects may include:

• Nausea

• Diarrhea

• Decreased appetite

• Vomiting

• Constipation

• Upset stomach

• Abdominal pain

Zepbound (tirzepatide)

Like Mounjaro, Zepbound is a dual GLP-1/GIP receptor agonist. It is the most effective weight loss medication currently available, with an average 72-week weight loss of 15%–21%, depending on the dose.

Zepbound is FDA-approved for chronic weight management in adults with obesity or with overweight and a weight-related health condition. It is also approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

Zepbound is a once-weekly injection and comes in six dosage strengths. Common side effects of Zepbound may include:

• Nausea

• Diarrhea

• Vomiting

• Constipation

• Abdominal pain

• Upset stomach

• Rash or reaction at the injection site 

• Fatigue

• Allergic reactions to the active ingredient

• Belching

• Hair loss

• Gastroesophageal reflux disease (GERD)

See if you qualify

Foundayo (orforglipron)

Foundayo (orforglipron) is an oral GLP-1 that is FDA-approved for weight loss in adults with obesity or with overweight and a weight-related health condition. It is not approved to treat type 2 diabetes.

In clinical trials, Foundayo produced an average weight loss of up to 11.1% in 72 weeks, depending on the dose.

Like the Ozempic and Wegovy pills, Foundayo is taken daily in the morning on an empty stomach, at least 30 minutes before food, beverages, or other medications. It comes in six dosage strengths. 

Common side effects of Foundayo include:

• Nausea

• Constipation

• Diarrhea

• Vomiting

• Upset stomach

• Abdominal pain

• Headache

• Bloating

• Fatigue

• Belching 

• Gastroesophageal reflux disease (GERD)

• Flatulence

• Hair loss 

Victoza (liraglutide)

Victoza (liraglutide) is similar to Ozempic in that it is FDA-approved to treat the same things: improving blood sugar control in people with type 2 diabetes, and reducing cardiovascular risk in those who also have heart disease. 

However, there are two major differences when looking at Victoza vs. Ozempic: Victoza is a daily injection, and it's also one of the few GLP-1s available as a generic. That said, studies suggest side effects may be more likely with Victoza, and Ozempic leads to more weight loss and better blood sugar control.

Common side effects of Victoza may include:

• Nausea

• Diarrhea

• Vomiting

• Decreased appetite

• Upset stomach

• Constipation 

Saxenda (liraglutide)

Saxenda (liraglutide) shares the same active ingredient as Victoza and is also a daily injection. It is FDA-approved for weight loss and is prescribed to people with obesity or with overweight and a weight-related health condition (such as high blood pressure, high cholesterol, or type 2 diabetes). 

Saxenda also shares the distinction of being available as a generic. Currently, it is the only GLP-1 approved for weight loss that’s available as a generic.

Common side effects of Saxendainclude:

• Nausea

• Diarrhea

• Constipation

• Vomiting

• Rash or reaction at the injection site 

• Headache

• Hypoglycemia (low blood sugar)

• Upset stomach

• Fatigue

• Dizziness

• Abdominal pain

• Increased lipase levels (a potential warning sign of acute pancreatitis)

• Fever

• Stomach flu

Studies comparing liraglutide to semaglutide have found that side effects may be more common with Saxenda than with Ozempic. However, Saxenda does produce more weight loss than Ozempic.

Trulicity (dulaglutide)

Like Ozempic, Trulicity (dulaglutide) is a once-weekly injectable medication that improves blood sugar levels in people with type 2 diabetes and, in people who also have heart disease, reduces their cardiovascular risk. 

Common gastrointestinal side effects of Trulicity may include:

• Nausea

• Diarrhea

• Vomiting

• Abdominal pain

• Decreased appetite

Studies comparing Ozempic vs. Trulicity have found Ozempic produces more weight loss and better blood sugar control.  

TL;DR: As you can see, there are a number of alternatives to Ozempic. Some may have contraindications with other medications or health conditions. So, it's important to share your full medical history and current medications with your healthcare provider before starting treatment or switching from Ozempic to one of these options.

We may have several years before a generic Ozempic becomes available in the US. Until then, the Ozempic pill and injection remain available as a brand-name medication, along with several other GLP-1 treatment options.

• Currently, Ozempic is not available as a generic in the United States (although generics are available in Canada).

• The drug maker Novo Nordisk’s exclusive patent on semaglutide, Ozempic’s active ingredient, doesn’t expire until December 5, 2031.

• The earliest a generic Ozempic could be available in the US would be after that expiration date, so possibly 2032.

• Alternative treatments to Ozempic for type 2 diabetes include Trulicity, Mounjaro, Victoza, or generic liraglutide.

• Alternatives for weight loss include the Wegovy pill or injection, Zepbound, Saxenda, or generic liraglutide.